Prognostic factors for uterine adenosarcoma: a review

References

• Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study. Cancer. 1993;71:1702–1709.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–139.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355–364.
   PubMed Web of Science ®Google Scholar
• Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93:204–208.
   PubMed Web of Science ®Google Scholar
• Nathenson MJ, Ravi V, Fleming N, et al. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18:68.
   PubMed Web of Science ®Google Scholar
• Clement PB, Scully RE. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of Mullerian mixed tumor. Cancer. 1974;34:1138–1149. .
   PubMed Web of Science ®Google Scholar
• Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21:363–381. .
   PubMed Web of Science ®Google Scholar
• Kaku T, Silverberg SG, Major FJ, et al. Adenosarcoma of the uterus: a gynecologic oncology group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11:75–88.
   PubMed Web of Science ®Google Scholar
• Pinto A, Howitt B. Uterine Adenosarcoma. Arch Pathol Lab Med. 2016;140:286–290.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Prat J. Pathology of mixed Mullerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011;25:705–718.
   PubMed Web of Science ®Google Scholar
• Benito V, Lubrano A, Arencibia O, et al. Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J Gynaecol Obstetrics. 2009;107:44–49.
   PubMed Web of Science ®Google Scholar
• Blom R, Guerrieri C. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer. 1999;9:37–43.
   PubMed Web of Science ®Google Scholar
• Tanner EJ, Toussaint T, Leitao MM Jr., et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129:140–144.
   PubMed Web of Science ®Google Scholar
• Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol. 1989;13:28–38. .
   PubMed Web of Science ®Google Scholar
• Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135:455–461. .
   PubMed Web of Science ®Google Scholar
• Bernard B, Clarke BA, Malowany JI, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013;131:634–639.
   PubMed Web of Science ®Google Scholar
• Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol. 2009;33:278–288.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Vasuratna A, Edwards C, et al. Clinicopathologic analysis of Mullerian adenosarcoma: the M.D. Anderson cancer center experience. Oncol Rep. 1998;5:939–944.
   PubMed Web of Science ®Google Scholar
• Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer. 1981;48:354–366.
   PubMed Web of Science ®Google Scholar
• Krivak TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol. 2001;83:89–94.
   PubMed Web of Science ®Google Scholar
• Arend R, Bagaria M, Lewin SN, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119:305–308.
   PubMed Web of Science ®Google Scholar
• Machida H, Nathenson MJ, Takiuchi T, et al. Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecol Oncol. 2017;144:524–530.
   PubMed Web of Science ®Google Scholar
• Nathenson MJ, Conley AP, Lin HY, et al. The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes. Int J Gynecol Cancer. 2018;1. [ Epub ahead of print]. doi:10.1097/IGC.0000000000001306
   PubMed Web of Science ®Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104:177–178.
   PubMed Web of Science ®Google Scholar
• Eichhorn JH, Young RH, Clement PB, et al. Mesodermal (Mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26:1243–1258.
   PubMed Web of Science ®Google Scholar
• Chin PS, Chia YN, Lim YK, et al. Diagnosis and management of Mullerian adenosarcoma of the uterine cervix. Int J Gynaecol Obstet. 2013;121:229–232.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang YW, Li YF. Primary vaginal sarcoma: experience of a regional cancer center in China. J Obstet Gynaecol Res. 2015;41:1463–1468.
   PubMed Web of Science ®Google Scholar
• Kao GF, Norris HJ. Benign and low grade variants of mixed mesodermal tumor (adenosarcoma) of the ovary and adnexal region. Cancer. 1978;42:1314–1324.
   PubMed Web of Science ®Google Scholar
• Fleming NA, Hopkins L, de Nanassy J, et al. Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol. 2009;22:e45–51.
   PubMedGoogle Scholar
• Clement PB, Scully RE. Extrauterine mesodermal (Mullerian) adenosarcoma: a clinicopathologic analysis of five cases. Am J Clin Pathol. 1978;69:276–283.
   PubMed Web of Science ®Google Scholar
• Clement PB, Scully RE. Uterine tumors with mixed epithelial and mesenchymal elements. Semin Diagn Pathol. 1988;5:199–222.
   PubMed Web of Science ®Google Scholar
• McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010;17:122–129.
   PubMed Web of Science ®Google Scholar
• McCluggage WG, Lioe TF, McClelland HR, et al. Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer. 2002;12:128–132.
   PubMed Web of Science ®Google Scholar
• Howitt BE, Sholl LM, Dal Cin P, et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol. 2015;235:37–49. .
   PubMed Web of Science ®Google Scholar
• Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32:1013–1021. .
   PubMed Web of Science ®Google Scholar
• Van Mieghem T, Abeler VM, Moerman P, et al. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol. 2005;99:493–496.
   PubMed Web of Science ®Google Scholar
• Howitt BE, Dal Cin P, Nucci MR, et al. Involvement of chromosome 8 in Mullerian adenosarcoma. Int J Gynecol Pathol. 2017;36(1):24–30.
   Web of Science ®Google Scholar